Table 3.
Adjusted hazard ratios for treatment persistence according to the biologic agent used.
| Adalimumab | Infliximab | Vedolizumab | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Age at onset | 0.974 (0.947–1.002) | .064 | 1.028 (0.997–1.060) | .073 | 1.006 (0.970–1.042) | .758 |
| Extent at diagnosisa | ||||||
| E1—Proctitis | 1.440 (0.387–5.351) | .587 | 1.020 (0.322–3.231) | .973 | 0.360 (0.043–3.045) | .348 |
| E2—Left-sided colitis | 3.054 (1.096–8.505) | .033 | 0.337 (0.109–1.038) | .058 | 0.100 (0.011–0.875) | .038 |
| E3—Pancolitis | Reference | Reference | Reference | |||
| Prior treatment with NTAb | ||||||
| No prior exposure | Reference | Reference | Reference | |||
| One prior exposure | 1.174 (0.382–3.610) | .779 | 2.449 (0.712–8.419) | .155 | 1.056 (0.267–4.180) | .938 |
| Two prior exposure | – | 5.285 (1.103–25.324) | .037 | 1.512 (0.263–8.704) | .644 | |
P-values under the specified threshold were typed using bold text.
Abbreviations: HR = hazard ratio; NTA = new therapeutic avenues.
Proportion calculated on total available data.
Includes exposition to golimumab, tofacitinib, ustekinumab, and the 3 studied molecules.